RBC and plasma folate concentrations by treatment group at 16 and 20 weeks
| Outcome | 0 mg (n=110)* | 0.4 mg (n=110)* | 2.8 mg (n=111)* | 2.8 vs 0 mg | 0.4 vs 0 mg | 2.8 vs 0.4 mg | |||
| Mean difference (95% CI)† | P value‡ | Mean difference (95% CI)† | P value‡ | Mean difference (95% CI)† | P value‡ | ||||
| RBC folate, nmol/L§ | |||||||||
| Baseline | 466±136 | 474±136 | 507±168 | ||||||
| 16 weeks | 466±158 | 554±146 | 851±208 | 355 (316 to 394) | <0.0001 | 84 (54 to 113) | <0.0001 | 271 (234 to 309) | <0.0001 |
| 20 weeks | 443±134 | 534±155 | 766±183 | 293 (259 to 327) | <0.0001 | 82 (52 to 113) | <0.0001 | 211 (173 to 249) | <0.0001 |
| Plasma folate, nmol/L§ | |||||||||
| Baseline | 10.1±4.0 | 10.3±4.3 | 11.6±6.6 | ||||||
| 16 weeks | 10.7±4.8 | 15.6±7.2 | 31.5±14.5 | 19.6 (16.9 to 22.4) | <0.0001 | 4.8 (3.5 to 6.0) | <0.0001 | 14.9 (12.0 to 17.8) | <0.0001 |
| 20 weeks | 13.5±10.3 | 15.2±6.2 | 24.2±11.0 | 9.5 (6.8 to 12.3) | <0.0001 | 1.5 (−0.5 to 3.6) | 0.15 | 8.0 (5.7 to 10.3) | <0.0001 |
*Values are mean±SD based on the raw data of the intention-to-treat population.
†Mean differences are adjusted for the baseline value of the outcome.
‡Statistical significance set at p<0.0167 for pairwise comparisons of treatment groups.
§P<0.0001 for treatment group by time point interaction test.
RBC, red blood cell.